Led · Seed · Apr 2023

CND Life Sciences develops objective biomarker-based diagnostics for neurodegenerative diseases and is best known for the Syn-One Test, a proprietary skin biopsy-based LDT designed to detect phosphorylated alpha-synuclein and other pathological markers. Since 2020, Syn-One has been ordered by more than 4,000 neurologists and clinicians to support diagnostic evaluations for over 60,000 patients, and it is supported by a growing body of peer-reviewed clinical evidence. The company collaborates with biopharmaceutical firms on clinical trials and conducts studies on early disease detection and synuclein quantification. CND is positioning Syn-One as part of a broader multimodal biomarker capability to aid diagnosis, disease characterization, and earlier intervention. Financially, the company recently secured growth financing led by S-Curve Partners to support commercial growth, product innovation, strategic partnerships, and expanded access to its platform.

Participated · Seed · Apr 2022

Ugami offers a financial rewards platform for gamers built around the Ugami Debit Card and Ugipoints, a rewards currency redeemable for cash or merchandise. The company decentralizes its rewards program across gaming and technology brands, and users can shop a curated store featuring partners such as Best Buy, Nvidia, Steam, Xbox, PlayStation and Nintendo. Ugami’s app supports physical and virtual debit cards with zero fees and includes features like a 4X Ugipoints boost, streaks, badges, daily spins and a level/status system. It also provides an ATM finder for fee-free cash access across a 55,000-machine network. Led by CEO Hector Hulian and based in Miami, Florida, Ugami plans to use new funding to accelerate growth, expand operations and broaden its business reach. In April 2022 Ugami raised $4.8M in Seed funding.